ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that on 08 June 2026 it bought back 265,800 H shares on the Hong Kong Stock Exchange, paying a total of HKD 0.83 million. The shares were repurchased within a price band of HKD 3.04 to HKD 3.27, translating into a volume-weighted average cost of HKD 3.11 per share.

The transaction represents 0.0632% of the company’s outstanding H shares prior to the buyback. All repurchased shares have been retained as treasury stock.

Following the transaction, shares in issue (excluding treasury shares) fell to 420.21 million, while the total issued share capital remained unchanged at 420.48 million. Treasury stock now stands at 265,800 shares.

The buyback was executed under the mandate approved on 28 May 2026, which authorises repurchases of up to 43.15 million shares. To date, 0.62% of this limit has been utilised. In accordance with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 08 July 2026.